US20130085569A1 - Crosslinker enhanced repair of knee meniscus - Google Patents

Crosslinker enhanced repair of knee meniscus Download PDF

Info

Publication number
US20130085569A1
US20130085569A1 US13/700,091 US201113700091A US2013085569A1 US 20130085569 A1 US20130085569 A1 US 20130085569A1 US 201113700091 A US201113700091 A US 201113700091A US 2013085569 A1 US2013085569 A1 US 2013085569A1
Authority
US
United States
Prior art keywords
patch
crosslinking agent
meniscus
delivery device
fixation device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/700,091
Other languages
English (en)
Inventor
Thomas P. Hedman
Paul Slusarewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORTHOPEUTICS LP
Original Assignee
ORTHOPEUTICS LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ORTHOPEUTICS LP filed Critical ORTHOPEUTICS LP
Priority to US13/700,091 priority Critical patent/US20130085569A1/en
Assigned to ORTHOPEUTICS, L.P. reassignment ORTHOPEUTICS, L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEDMAN, THOMAS P., SLUSAREWICZ, PAUL
Publication of US20130085569A1 publication Critical patent/US20130085569A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/30756—Cartilage endoprostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/505—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/38—Joints for elbows or knees
    • A61F2/3872—Meniscus for implantation between the natural bone surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Definitions

  • the present invention relates to protein crosslinking reagents for the surgical repair of torn knee menisci in humans or similar connective tissue structures in animals such as the stifle joint meniscus in equines.
  • the menisci of the knee are a pair of crescent-shaped fibrocartilaginous structures attached to the planar apical surface of the tibia. They contact the outer region of the femoral articular cartilage surface and as such play an important role in both load transmission and in maintaining the stability of the joint [1-6].
  • menisci While 65-75% of the mass of the menisci consists of water, the remaining constituents are primarily proteins with the most common (75%) being type I collagen [7], and damage to this tissue is one of the most common causes of knee injury and results in surgery to some 850,000 patients per year in the US [8]. Symptoms of meniscal tears are primarily localized pain and swelling but, in cases where fragments of the damaged meniscus lodge between the articulating surfaces of the joint, catching sensations and (in the worst case) locking of the joint can occur.
  • the first line of treatment for meniscal tears are non-surgical, e.g. rest, icing, physical therapy and/or non-steroidal anti-inflammatory drug (NSAID) treatment. Surgery is indicated for patients who do not respond to physical therapy, who cannot or are unable to sacrifice the time required for potentially unsuccessful therapy and for those with locked joints.
  • NSAID non-steroidal anti-inflammatory drug
  • stem cell therapy [15,16]; trephination from the vascular to avascular region to facility greater nutrient flow and promote in-growth of vasculature [17-19]; micro-fracture of the intercondylar notch which may release cytokines or autologous stem cells to aid in the repair process [20]; thermal welding of the tear [21]; enhancement of fibroblast proliferation using RF radiation [22,23]; use of fibrin clots to both provide stimuli for both chemotaxis and proliferation of regenerative cells [24-26], sometimes in conjunction with laser soldering [27]; meniscal or synovial rasping to promote healing via the release of growth factors from the tissue [28-31]; and synovial flap grafting at the repair site to provide vasculature [32].
  • meniscal replacement using both artificial implants and allografts is becoming a treatment option in the case of severe tears where meniscectomy is the only other treatment option [33-40].
  • meniscal replacement using both artificial implants and allografts is becoming a treatment option in the case of severe tears where meniscectomy is the only other treatment option [33-40].
  • meniscectomy is the only other treatment option [33-40].
  • the possibility of stabilizing allografts and artificial implants against biodegradation using ex vivo protein crosslinking has been explored [41-44].
  • the inventors are, however, unaware of any prior art with regard to crosslinking of the native meniscus in situ.
  • a method of treating a tear in a knee meniscus of a patient in need of such treatment includes exposing the torn knee meniscus to a protein crosslinker (an agent that crosslinks protein) during surgery to repair the tear.
  • exposing includes: a) injecting the crosslinker into a knee joint capsule containing the torn knee meniscus; b) injecting the crosslinker into or onto the torn knee meniscus; or c) contacting the torn knee meniscus with a delivery device comprising the crosslinker; or d) any combination thereof.
  • the crosslinker is a compound or substance that can crosslink proteins.
  • the delivery device in any embodiment can include a patch or fixation device comprising the crosslinker.
  • the fixation device may be an arrow, dart, tack or suture.
  • a patch or fixation device may be biodegradable or non-biodegradable, and may comprise a basic salt, which may be an inorganic or organic basic salt.
  • the patch may be porous, and may have crosslinker embedded in the pores of the patch.
  • a crosslinker in a patch may be adhered to one side of the patch as part of a semi-solid formulation.
  • the patch or fixation device may in addition be coated with one or more layers of crosslinker-containing biodegradable polymer.
  • each layer may contain a basic salt, and may contain the same or different basic salt as another layer.
  • each layer may contain the same or different crosslinker as another layer.
  • the crosslinker varies from layer to layer.
  • the patch may be affixed to the meniscus with a bio-compatible adhesive.
  • the patch may be affixed to the meniscus by an associated fixation device such as an arrow, dart, tack or suture.
  • the associated fixation device may itself include a crosslinker, which may be the same or different crosslinker as that in the patch.
  • the torn knee meniscus is treated without contracting collagen fibers in the torn knee meniscus by heating.
  • a delivery device for contacting the knee meniscus comprises a protein crosslinker.
  • FIG. 1 is a drawing depicting a stylized human knee meniscus with a “parrot beak” type tear.
  • One aspect relates to various biodegradable fixation devices that contain one or more protein crosslinking reagents for the surgical repair of tears of the meniscus of the knee in humans or similar connective tissue structures in animals such as the stifle joint meniscus in equines. Also described are associated methods for repair of tears of the knee meniscus in humans or similar connective tissue structures in animals such as the stifle joint meniscus in equines.
  • the devices can take various forms including, but not limited to, sutures, tacks, arrows and darts. These devices can be produced using any biodegradable and biocompatible polymer or mixtures of polymers such as, but not limited to, polylactic acid or poly glycolic acid.
  • One or more crosslinking agents may be incorporated into the device. Additionally, the crosslinker can be incorporated into a biodegradable patch which is overlain onto the damaged area of the meniscus during surgery. Alternatively this patch could be made of a non-degradable material and removed at a time following surgery once sufficient crosslinker has been released to facilitate tissue repair.
  • these reagents are slowly released from the device as it degrades and thereby enter into, and react with, the tissue to form covalent crosslink bonds.
  • These bonds serve to both strengthen the tissue against further and/or future tearing and also increase the permeability of the tissue to nutrients from the blood supply, thereby enhancing the natural healing process.
  • the increase in tissue permeability conferred by the crosslinking will increase the proportion of meniscal tear patients who can be treated surgically since healing using current methods can only occur in regions with sufficient vascular nutrient supply.
  • Another aspect relates to the treatment of meniscal tears during surgery with protein crosslinking reagents to modify the mechanical properties and permeability of the meniscal tissue in order to reduce the possibility of further tearing, increase the strength of the tissue and enhance the natural repair process.
  • Crosslinking of tissue is used extensively to modulate both the mechanical properties and chemical stability of collagenous tissues [45-52]. Historically, crosslinking has been conducted ex vivo to modulate the mechanics and stability of tissue implants, and has been considered with respect to producing allografts for meniscal implant [41], but was not directed at treatment of native meniscal tissues in vivo and in situ, in the tissues original and natural position. Approaches aimed at injection of crosslinkers into native, unmodified tissues in vivo and in situ are also being developed by the inventors (U.S. Pat. No. 7,435,722, and U.S. patent application Ser. No. 10/230,671, both incorporated by reference herein) and others [53] for treatment of the spinal disc.
  • crosslinker will confer increased tear resistance to the tissue and reduce the possibility of further propagation of the tear as it heals (U.S. application Ser. No. 11,712,684, incorporated by reference herein). This would in turn ameliorate the main disadvantage of fixation devices compared to sutures while maintaining their benefits. If the crosslinker delivery-fixation device is a suture or another device capable of tissue fixation, the crosslinker delivery will further augment the tear resistance of the repair.
  • crosslinking has been shown to increase the permeability of collagenous tissues [41,54,55] and thus may increase the permeability of the meniscus.
  • the avascular portions of the meniscus (which do not heal well, if at all, in vivo) are capable of healing in vitro when supplied with sufficient nutrients [11].
  • the resulting increased supply of nutrients and oxygen to the avascular tissue may both increase the success of the procedure for deeper tears as well as increase the depth at which a tear is considered as a candidate for repair versus meniscectomy.
  • Particular embodiments combine the beneficial properties of protein crosslinking to improve upon currently used surgical techniques for meniscal repair.
  • a torn knee meniscus is treated without contracting collagen fibers in the torn knee meniscus by heating.
  • Heat denaturation of collagenous tissues degrades the tissue by disruption of native crosslinks and tissue structure.
  • the device and methods of exposing the meniscus tissues to the crosslinker may be applied to non-heated, unmodified, native tissues.
  • the device and methods may be applied without heating, contracting or denaturing the native tissue, or any combination thereof.
  • the native tissue crosslinks are thus augmented or increased by number by exposure to the crosslinker.
  • the in situ crosslinking method and/or devices may be applied to previously implanted non-native tissue implants or meniscus replacement materials that have not been denatured and/or shrunken by heating.
  • the meniscal tissue is pre-treated prior to, or instead of repair by direct injection of crosslinking solution into the capsule of the knee joint or onto or into the damaged tissue itself prior to repair of the tissue.
  • This treatment strengthens the tissue, increases tear resistance, and, in addition, allows for the surgical repair of some tears that will not normally be candidates for repair surgery (due to their inability to heal because of their distance from the blood supply) by increasing the permeability of the tissue.
  • the crosslinker diffuses into, and crosslinks, the meniscal tissue, strengthening and increasing tear resistance of the tissue, while also improving the ability of nutrients from the outer vascular regions to diffuse into the inner regions to promote natural healing over a larger area of the meniscus.
  • the crosslinker is incorporated into the fixation device itself.
  • the crosslinker is then released into the tissue in a sustained manner following surgery as the fixation device degrades providing the benefits in physical properties and permeability described above.
  • Solid or liquid crosslinker may be incorporated into the device by addition to the molten polymer prior to casting, molding or spinning Alternatively the crosslinker may be co-solubilized with the polymer in a suitable solvent (for example, acetone) and then incorporated into the device by removal of the solvent by evaporation or by precipitation (for example, by the addition of ethanol) of the polymer as described previously [56,57].
  • the crosslinker and polymer may also be solubilized separately and mixed prior to precipitation in either the same solvent or different (miscible) solvents.
  • the solid crosslinker may also be mixed into the polymer gum formed by precipitation of solubilised polymer and prior to molding.
  • the rate of crosslinker release can be controlled by varying the amount or concentration of the crosslinker incorporated into the device as well as by selecting polymers or other materials with differing in vivo degradation rates.
  • the crosslinker may be co-solubilized with the polymer in a suitable solvent, solubilized separately in the same solvent and then mixed, or solubilized separately in different miscible solvents and then mixed, and a pre-formed fixation device immersed in this solution.
  • a fixation device containing an outer layer of biodegradable plastic-embedded crosslinker will be produced.
  • the polymer in the outer layer may be different to that of the underlying device both in chain length and/or composition and may be varied, for example, in order to provide different release rates of crosslinker as needed.
  • the rate, duration and extent of crosslinker release can be controlled by varying the amount or concentration of the crosslinker incorporated into solvent solution (and therefore the outer layer of the device) as well as by sequential dipping/drying of the fixation device into the crosslinker/polymer/solvent mixture to produce different thicknesses of crosslinker-containing polymer at the surface of the device.
  • several crosslinker impregnated outer layers may be used with varying crosslinker amount or concentration and polymer compositions such that the rate of release of crosslinker can be varied as desired. For instance, an initial high rate of crosslinker release can be followed by a low rate of crosslinker release for an extended length of time.
  • salts are also incorporated as solid suspensions into the polymer matrix.
  • Such salts could be inorganic (for example, but not limited to, calcium carbonate, calcium hydroxyapatite or sodium bicarbonate) or organic (for example, but not limited to, 2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
  • the crosslinker is impregnated by one of the methods described above into a flat, biodegradable polymer patch.
  • the patch could contain pH conditioning agents and multiple layers of crosslinking agents as described above.
  • the patch (which could be rolled up and inserted via a catheter) is laid over the repaired tissue such that crosslinker is delivered to the meniscus as the patch dissolves and while the patch offers some physical protection to the damaged meniscal tissue as it heals.
  • the surface of the patch opposite to the meniscus additionally provides a smooth bearing surface to the articular cartilage of the femur.
  • the patch may be attached to the tissue using fixation devices such as, but not limited to, arrows, darts, tacks or suture.
  • fixation devices may or may not contain additional (including different) crosslinking agent.
  • the patch may also be attached using a suitable biocompatible adhesive.
  • suitable adhesives would be poly(glycerol-co-sebacate acrylate) [60], oleic methyl esters [61] or alkyl ester cyanoacrylates [62].
  • the material of the patch consists of a non-absorbable polymer.
  • the patch is placed onto the meniscus during the arthroscopic procedure and can be removed at a subsequent time.
  • the patch may be designed to remain inside the knee as a permanent implant to supplement the mechanical function of the meniscus.
  • the patch may be attached to the meniscus as stated above.
  • Possible, non-limiting, polymers include polyvinylacetate, polyvinylchloride, polypropylene, polyetheretherketone (PEEK), polysulfone, polyethersulfone, polytetrafluoroethylene, polyethylene, polyurethane, polyetherimide and polycarbonate.
  • the non-absorbable patch is either coated or impregnated with crosslinker.
  • the material of the patch could be porous so that the crosslinker or combination of crosslinkers is imbedded within the pores, or non-porous and coated with crosslinker.
  • the size and the tortuosity of the pores can be varied in order to control the release rate and duration of release of the imbedded crosslinker(s).
  • the crosslinker could be in solid form, in solution in a suitable carrier or dissolved or suspended in a semi-solid formulation.
  • the crosslinker is encapsulated within micro- or nano-particles which are suspended in any of the above matrices or attached directly, either covalently or non-covalently to the surface of the non-absorbable patch.
  • the crosslinker could be incorporated into a biodegradable (absorbable) polymer and then used to either coat or impregnate the non-absorbable patch.
  • crosslinkers A large number of protein crosslinkers could be used in conjunction with the present invention.
  • Some such crosslinkers that have been used in the area of tissue engineering include, but are not limited to: D- or L-Threose [63], genipin [64-67], Methylglyoxal [68], 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [69], proanthrocyanidin [47] and glutaraldehyde [70-72].
  • the crosslinker may be a single crosslinker or a combination of two or more crosslinkers.
  • crosslinkers differ between reagents [58] and that in some cases other chemicals can enhance their reactivity [53].
  • some detergents can also enhance the penetration of crosslinkers through collagenous tissues and therefore help to enhance their ability to crosslink the tissue[53].
  • some embodiments may include a chemical or detergent, or any combination thereof, that enhances the crosslinking ability of the crosslinker.
  • the application method involves a direct injection of crosslinker in a buffered reagent into the torn meniscus.
  • the crosslinker can be selected from several known minimally toxic crosslinking agents such as genipin at a level of up to 1200 micromoles and concentration of at least 5 mM (preferably 20-100 mM) and the buffer can be 25-250 mM EPPS 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) (preferably approximately 50 mM) at a pH of 7-10 (preferably 8) and optionally contain 25-250 mM of a phosphate salt (preferably 50 mM) to facilitate the crosslinking reaction and also optionally contain a co-solvent such as dimethyl sulfoxide (at 1-50%, preferably 10-20%) to increase the solubility of the crosslinker.
  • EPPS 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid
  • the crosslinker and conditioning agents are imbedded into a biodegradable meniscus fixation dart.
  • the crosslinker can be any of several known minimally toxic crosslinking agents such as genipin or methylglyoxal at a level of about 1-10 mg per dart, though more can also be incorporated.
  • the fixation device can also optionally contain an alkaline salt such as calcium hydroxyapatite to maintain an elevated pH as the device degrades at a level of about 5-50% by weight of the polymer (preferably about 15-30%).
  • the crosslinker and conditioning agents are imbedded into a biodegradable suture suitable for meniscus repair using standard repair techniques.
  • the crosslinker can be any of several known minimally toxic crosslinking agents such as genipin or methylglyoxal at a level of about 0.1-10% by weight of the polymer (preferably about 1-5%).
  • the suture can also optionally contain an alkaline salt such as sodium bicarbonate to maintain an elevated pH as the device degrades at a level of about 5-50% by weight of the polymer (preferably about 5-15%).
  • the crosslinker and conditioning agents are imbedded into a biodegradable meniscus repair patch.
  • the crosslinker can be selected from any of several known minimally toxic crosslinking agents such as genipin at a level of about 1-250 mg per patch (preferably about 5-20 mg).
  • the patch can also optionally contain an alkaline salt such as calcium carbonate to maintain an elevated pH as the device degrades at a level of about 5-50% by weight of the polymer (preferably about 15-30%).
  • the crosslinker embedded into the patch may, therefore, be incorporated into a formulation that is designed to optimize its activity by the suitable adjustment or addition of, but not exclusively, pH, ionic strength, cations, anions, phosphate ions, and/or surfactants.
  • crosslinkers can exert different mechanical effects [53].
  • combination of crosslinkers may also be incorporated into embodiments in order to modulate the final mechanical properties of the meniscal tissue.
  • the fixation device may contain a mixture of two or more crosslinking agents.
  • the bulk of the fixation device or patch contains one or more crosslinkers that are incorporated into the device during the molding stage as described above.
  • the device is then coated using a solvent mixture as described above but containing a different crosslinker or mixture of crosslinkers.
  • the device may be coated with additional layers of material by applying molten polymer containing crosslinker with or without additional agents, or a solvent-precipitated polymer gum containing crosslinker with or without additional agents.
  • a device might contain a crosslinker that increases tissue tear resistance but be coated with a crosslinker that preferentially increases permeability. In this manner the device will first enhance permeability of the tissue to both rapidly aid in the initiation of natural repair and prepare the tissue for ready diffusion of the second crosslinker, and only later release a crosslinker to strengthen the tissue.
  • the outer layer may contain a strengthening crosslinker to provide immediate improvements in meniscal tear resistance while the crosslinker that enhances permeability is released later to help facilitate natural repair.
  • a stylized human knee meniscus 2 with a “parrot beak” type tear 4 is depicted.
  • a patch 6 of crosslinker-impregnated material is placed over the damaged tissue.
  • the shaded area 8 depicts the position of the patch following attachment.
  • the patch may additionally be attached using typical surgical fixation devices or by addition of a suitable biocompatible solvent or adhesive to the side of the patch in contact with the meniscus. Over time crosslinker will diffuse out of the patch and into the tissue, both strengthening it and facilitating the diffusion of nutrients into the damaged area by increasing the tissue permeability.
  • a patient may be a person or an animal.
  • embodiments that involve the knee meniscus may be applied to similar connective tissue structures in animals, such as the stifle joint meniscus in equines.
  • connective tissue structures in animals such as the stifle joint meniscus in equines.
  • a radial tear of a human knee meniscus may be repaired by the present methods and devices in a number of embodiments.
  • Some embodiments involve implementation of standard arthroscopic procedures for meniscal repair using darts containing a crosslinking and a pH modulating reagent.
  • the fixation darts are manufactured as follows. One gram of 50:50 poly-D,L-lactide-co-glycolide polymer (average molecular weight of 53 kDa) is dissolved in 6 ml of acetone and then precipitated by addition of 10 ml of pure ethanol. Two hundred mg of sodium bicarbonate and 6 mg of genipin crosslinker are added to and mixed with the precipitated polymer prior to using the mixture to mould three meniscal dart devices which are dried under vacuum to solidify the polymer and remove the solvents.
  • Some embodiments involve implementation of standard arthroscopic procedures for meniscal repair using biodegradable sutures which are produced by extruding polydioxanone in the presence of 10% (w/w) of a 40% solution of methylglyoxal.
  • Some embodiments involve direct injection into the meniscal tissue in the region of the tear a buffered crosslinking reagent.
  • the injection may be administered using standard sterile intracapsular injection techniques and fluoroscopic, arthroscopic, or any equivalent or superior imaging technology and techniques that allow for simultaneous injections.
  • the injected solution contains 40 mM genipin in a buffer consisting of 50 mM 3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS) and 50 mM sodium triphosphate at a pH of 8.0.
  • EPPS 4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid
  • the patient should avoid flexion-extension or weight bearing of the knee for a period of time following the injection, approximately 1 hour, to allow for diffusion of the reagent and initial crosslink formation within the meniscal tissue, followed by a period of light movement and intermittent weight bearing to encourage further movement through the tissue of unreacted reagent and to aid in the introduction of oxygen to expedite the crosslinking reactions.
  • a direct injection of this type can be followed immediately or at a later date with use of a crosslinker impregnated repair device such as a dart or suture.
  • the direct injection of a buffered crosslinking reagent into the meniscus can follow meniscal repair using standard fixation devices or crosslinker impregnated fixation devices.
  • Some embodiments involve arthroscopic or minimally invasive delivery and fixation of a meniscal repair patch to the inferior or superior articular surface of the torn meniscus.
  • the meniscal repair patch is prepared from 2 grams of poly lactic acid by dissolving the polymer in 12 ml of acetone and then precipitating by addition of 20 ml of pure ethanol. Six hundred mg of calcium carbonate and 20 mg of genipin crosslinker are added to and mixed with the precipitated polymer prior to molding into the final device and drying under vacuum.
  • the patch may or may not be attached to the meniscal tissue using fixing devices such as darts, tacks or sutures which may or may not also contain crosslinking agents (for example, as in Example 1).
  • meniscal mechanical properties including tear resistance due to the present methods and devices can be measured using human or bovine cadaveric meniscal explants and in vitro experimental methods briefly summarized here.
  • An appropriate number of tissue specimens are included in the study according to previously documented variances in mechanical properties of the selected tissue type. According to the inventors' previously published protocol (Slusarewicz, et al., 2011, Spine, “Optimization of protein crosslinking formulations . . . ” [49]), two adjacent circumferential dumbbell-shaped specimens are excised from the inner region of sixteen medial or lateral menisci for tensile testing.
  • One specimen from each pair is treated with a crosslinking agent either via soaking in a buffered crosslinking solution such as 40 mM genipin in a buffer consisting of 50 mM 3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS) and 50 mM sodium triphosphate at a pH of 8.0, or injecting approximately 0.1-0.5 ml of such a buffered crosslinking reagent using a small, greater than 20 gauge, or insulin-sized needle. Control specimens are mock-treated (soaked or injected) using the same buffer without crosslinker.
  • a buffered crosslinking solution such as 40 mM genipin in a buffer consisting of 50 mM 3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS) and 50 mM sodium triphosphate at a pH of 8.0, or injecting approximately 0.1-
  • Samples are subjected to strain-rate controlled tensile testing until failure using a suitable materials testing system and soft-tissue compatible clamps to hold the ends of the dumbbell-shaped specimens without tearing or damaging the specimens at the clamping site.
  • the data is normalized using the specimen's cross-sectional area measured with a rotating laser micrometer, and the yield stress, modulus, resilience, ultimate tensile stress, and toughness are calculated. Comparisons between groups are evaluated using Wilcoxon non-parametric paired analysis.
  • the effect of the crosslinking treatment is evidenced by a statistically significant and greater than 20% improvement in at least one of the measured mechanical properties following crosslinking treatment.
  • Transverse (transverse to the long axis of the meniscus specimens) tear resistance testing is conducted in the following manner.
  • 2 mm (axial) ⁇ 8 mm (transverse) inner meniscus longitudinal (circumferential) specimens are dissected from the rear half of sixteen lateral or medial knee menisci.
  • a transverse directed v-shaped notch defect is created with a scalpel in the mid-section of the specimen.
  • the thickness of the specimen in the region of the defect and the distance between the tip of the defect and the edge of the specimen opposite the defect are measured using a laser non-contacting micrometer.
  • a longitudinal (long axis of the meniscus specimen) tear testing protocol involves the use of sixteen front (cephalo) hemi-lateral meniscus specimens which are microtomed and dissected into ASTM style “pants legs” tear samples (12 mm ⁇ 2 mm ⁇ circumferential length with a cut following the longitudinal contour leaving 8 mm uncut) for longitudinal tear testing.
  • the thickness of the specimen in the uncut region and the distance between the “crotch” of the pants cut and the edge of the specimen opposite the cut are measured using a laser non-contacting micrometer.
  • Improvement in meniscal cell viability following crosslinking treatment can be quantified experimentally in a number of ways.
  • One method of quantifying this improvement is to measure the increase in tissue permeability associated with a crosslinking treatment of the present invention.
  • Permeability is analyzed using a Franz cell system.
  • Franz cells are glass chambers consisting of lower receptor and upper donor chambers with the sample sandwiched between them.
  • the lower chamber is filled with a suitable buffer while the donor chamber contains a suitable small probe molecule dissolved in buffer.
  • the permeability of the tissue governs the rate of the diffusion and presence of the probe molecule in the receptor fluid.
  • a suitable probe molecule penetrates but doesn't bind to the tissue.
  • Suitable probe molecules can be chromophores such as pnitrophenol or fluorophores such as fluorocein. In either case, a simple colorimetric or fluorometric (if greater sensitivity is required) assay is used to quantify the appearance of the probe in the receptor chamber. The baseline kinetics of penetration for normal meniscus is first quantified.
  • tissue samples are treated with crosslinking reagent either by soaking in 40 mM genipin in a buffer consisting of 50 mM 3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS) and 50 mM sodium triphosphate at a pH of 8.0, or by a direct injection of the buffered crosslinking reagent into the meniscus specimen as described in Example 5 above. An additional six controls are treated in a similar manner with buffer alone. Samples are then cut to the same thickness using a microtome.
  • EPPS 4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid
  • Kinetic analysis is conducted by periodically sampling and analyzing the receptor fluid, facilitating quantitative determination of tissue permeability.
  • the effect of the crosslinking treatment suggesting improved cell viability in this largely avascular tissue is evidenced by a statistically significant and greater than 40% increase in tissue permeability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Materials For Medical Uses (AREA)
US13/700,091 2010-05-27 2011-05-26 Crosslinker enhanced repair of knee meniscus Abandoned US20130085569A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/700,091 US20130085569A1 (en) 2010-05-27 2011-05-26 Crosslinker enhanced repair of knee meniscus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34897710P 2010-05-27 2010-05-27
PCT/US2011/038155 WO2011150218A1 (fr) 2010-05-27 2011-05-26 Réparation améliorée du ménisque du genou avec agent de réticulation
US13/700,091 US20130085569A1 (en) 2010-05-27 2011-05-26 Crosslinker enhanced repair of knee meniscus

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US11/975,072 Continuation-In-Part US8119599B2 (en) 2001-08-31 2007-10-17 Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
US12/715,737 Continuation-In-Part US8211938B2 (en) 2001-08-31 2010-03-02 Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
PCT/US2011/038155 A-371-Of-International WO2011150218A1 (fr) 2007-02-28 2011-05-26 Réparation améliorée du ménisque du genou avec agent de réticulation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/178,523 Continuation-In-Part US10278947B2 (en) 2007-02-28 2014-02-12 Crosslinker enhanced repair of connective tissues
US14/685,539 Division US9492592B2 (en) 2007-02-28 2015-04-13 Crosslinker enhanced repair of knee meniscus

Publications (1)

Publication Number Publication Date
US20130085569A1 true US20130085569A1 (en) 2013-04-04

Family

ID=45004384

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/700,091 Abandoned US20130085569A1 (en) 2010-05-27 2011-05-26 Crosslinker enhanced repair of knee meniscus
US14/685,539 Active US9492592B2 (en) 2007-02-28 2015-04-13 Crosslinker enhanced repair of knee meniscus

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/685,539 Active US9492592B2 (en) 2007-02-28 2015-04-13 Crosslinker enhanced repair of knee meniscus

Country Status (2)

Country Link
US (2) US20130085569A1 (fr)
WO (1) WO2011150218A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202143A1 (en) * 2001-08-31 2007-08-30 Hedman Thomas P Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints
US9192507B2 (en) 2001-08-31 2015-11-24 Orthopeutics, L.P. Tissue crosslinking for treatment of snoring and obstructive sleep apnea
US10278947B2 (en) 2007-02-28 2019-05-07 Orthopeutics, L.P. Crosslinker enhanced repair of connective tissues
US10828168B2 (en) 2017-05-10 2020-11-10 Howmedica Osteonics Corp. Patient specific composite knee replacement

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10549112B2 (en) 2012-07-20 2020-02-04 The General Hospital Corporation Apparatus for tissue irradiation and methods and kits utilizing the same
WO2014015274A1 (fr) * 2012-07-20 2014-01-23 The General Hospital Corporation Procédés pour la passivation de tissu
US10292381B2 (en) 2012-07-20 2019-05-21 The General Hospital Corporation Vessel treatment systems, methods, and kits
AU2014290513B2 (en) 2013-07-18 2017-07-27 The General Hospital Corporation Vessel treatment systems, methods, and kits
WO2024107362A1 (fr) 2022-11-15 2024-05-23 Spinal Simplicity, Llc Protection pour défaut rachidien

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729139A (en) * 1985-11-05 1988-03-08 Baxter Travenol Selective incorporation of a polymer into implantable biological tissue to inhibit calcification
WO2003007787A2 (fr) * 2001-07-16 2003-01-30 Depuy Products, Inc. Dispositif et procede de reparation et de regeneration du cartilage
US20070254005A1 (en) * 2004-08-26 2007-11-01 Pathak Chandraskekhar P Implantable Tissue Compositions and Method
US20090177228A1 (en) * 2004-07-01 2009-07-09 Optovent Ab Coated suture thread and production thereof
US20090311338A1 (en) * 2006-04-24 2009-12-17 Incept Llc Crosslinking methods and applications thereof
US20100080838A1 (en) * 2008-09-26 2010-04-01 Tyco Healthcare Group Lp Reactive Surgical Implant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4412190A1 (de) 1994-04-08 1995-10-12 Schreiber Hans Verfahren zur Anwendung rhenchodepressiver Sustanzen
US9314339B2 (en) * 2000-03-27 2016-04-19 Formae, Inc. Implants for replacing cartilage, with negatively-charged hydrogel surfaces and flexible matrix reinforcement
US6620846B1 (en) * 2000-08-02 2003-09-16 Closure Medical Corporation Absorbable adhesive compositions
EP1416888A4 (fr) * 2001-07-16 2007-04-25 Depuy Products Inc Dispositif et procede de regeneration du menisque
CN1578624A (zh) 2001-08-31 2005-02-09 南加利福尼亚大学 无毒性交联试剂在增强椎间盘及其他白纤维组织的抗疲劳性并减轻其机械性退化中的用途
WO2012006095A1 (fr) 2010-06-28 2012-01-12 Hedman Thomas P Réticulation tissulaire pour le traitement des ronflements et du syndrome des apnées obstructives du sommeil (saos)
US20030082116A1 (en) * 2001-09-28 2003-05-01 Closure Medical Corporation Adhesive compositions containing dual function stabilizers and active agents
US6812211B2 (en) * 2002-03-19 2004-11-02 Michael Andrew Slivka Method for nonsurgical treatment of the intervertebral disc and kit therefor
US7157428B2 (en) * 2003-11-26 2007-01-02 Histogenics, Corp. Method for treatment and repair of meniscal injuries

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729139A (en) * 1985-11-05 1988-03-08 Baxter Travenol Selective incorporation of a polymer into implantable biological tissue to inhibit calcification
WO2003007787A2 (fr) * 2001-07-16 2003-01-30 Depuy Products, Inc. Dispositif et procede de reparation et de regeneration du cartilage
US20090177228A1 (en) * 2004-07-01 2009-07-09 Optovent Ab Coated suture thread and production thereof
US20070254005A1 (en) * 2004-08-26 2007-11-01 Pathak Chandraskekhar P Implantable Tissue Compositions and Method
US20090311338A1 (en) * 2006-04-24 2009-12-17 Incept Llc Crosslinking methods and applications thereof
US20100080838A1 (en) * 2008-09-26 2010-04-01 Tyco Healthcare Group Lp Reactive Surgical Implant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hu et al., Tiss. Eng., 12(4):969-979 (2006) *
Peterson et al., Ann. Anat., 187:509-519 (2005) *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202143A1 (en) * 2001-08-31 2007-08-30 Hedman Thomas P Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints
US9192507B2 (en) 2001-08-31 2015-11-24 Orthopeutics, L.P. Tissue crosslinking for treatment of snoring and obstructive sleep apnea
US9918870B2 (en) 2001-08-31 2018-03-20 Orthopeutics, L.P. Tissue crosslinking for treatment of snoring and obstructive sleep apnea
US10278947B2 (en) 2007-02-28 2019-05-07 Orthopeutics, L.P. Crosslinker enhanced repair of connective tissues
US10980771B2 (en) 2007-02-28 2021-04-20 Orthopeutics, L.P. Crosslinker enhanced repair of connective tissues
US10828168B2 (en) 2017-05-10 2020-11-10 Howmedica Osteonics Corp. Patient specific composite knee replacement

Also Published As

Publication number Publication date
US20150217025A1 (en) 2015-08-06
WO2011150218A1 (fr) 2011-12-01
US9492592B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
US9492592B2 (en) Crosslinker enhanced repair of knee meniscus
US10786239B2 (en) Methods and procedures for ligament repair
US9849213B2 (en) Methods and products for tissue repair
AU2017291837B2 (en) Indirect method of articular tissue repair
Kerker et al. Cartilage repair: synthetics and scaffolds: basic science, surgical techniques, and clinical outcomes
US7157428B2 (en) Method for treatment and repair of meniscal injuries
CA2674524C (fr) Systeme in situ pour une reparation du tissu chondral et osseux intra-articulaire
US20080031923A1 (en) Biologic Replacement for Fibrin Clot
Paredes Development of a reinforced electrochemically aligned collagen bioscaffold for tendon tissue engineering applications

Legal Events

Date Code Title Description
AS Assignment

Owner name: ORTHOPEUTICS, L.P., KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEDMAN, THOMAS P.;SLUSAREWICZ, PAUL;REEL/FRAME:029466/0830

Effective date: 20121211

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION